The premise of capsid assembly modulators towards eliminating HBV persistence

Bassit, Leda; Amblard, Franck; Patel, Dharmeshkumar; Biteau, Nicolas G.; Chen, Zhe; Kasthuri, Mahesh; Zhou, Shaoman; Schinazi, Raymond F.

doi:10.1080/17460441.2023.2239701

Cited by 4 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV capsid assembly modulators (CAMs) can block multiple steps in the viral life cycle, including capsid trafficking to the nucleus, reverse transcription, pgRNA and polymerase protein co-packaging [31]. Strick-Marchand et al .…”

Section: Antiviral Therapies and Preclinical Models For Drug Evaluationmentioning

confidence: 99%

Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus

Allweiss,

Cohen,

Dias

et al. 2024

Journal of General Virology

View full text Add to dashboard Cite

Since its discovery in 1965, our understanding of the hepatitis B virus (HBV) replication cycle and host immune responses has increased markedly. In contrast, our knowledge of the molecular biology of hepatitis delta virus (HDV), which is associated with more severe liver disease, is less well understood. Despite the progress made, critical gaps remain in our knowledge of HBV and HDV replication and the mechanisms underlying viral persistence and evasion of host immunity. The International HBV Meeting is the leading annual scientific meeting for presenting the latest advances in HBV and HDV molecular virology, immunology, and epidemiology. In 2023, the annual scientific meeting was held in Kobe, Japan and this review summarises some of the advances presented at the Meeting and lists gaps in our knowledge that may facilitate the development of new therapies.

show abstract

Section: Antiviral Therapies and Preclinical Models For Drug Evaluationmentioning

confidence: 99%

Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus

Allweiss,

Cohen,

Dias

et al. 2024

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…Monocytes and macrophages are also involved in the phagocytosis and clearance of viral particles and infected hepatocytes, contributing to viral containment. By phagocytosing infected hepatocytes, macrophages help to contain viral replication and reduce viral load[ 50 , 51 ]. The dynamic interplay between macrophages and monocytes in HBV reactivation extends beyond their direct anti-viral functions.…”

Section: Possible Immunological Mechanisms Of Hbv Reactivationmentioning

confidence: 99%

Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies

Ma,

Yan,

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

Hepatitis B virus (HBV) reactivation is a clinically significant challenge in disease management. This review explores the immunological mechanisms underlying HBV reactivation, emphasizing disease progression and management. It delves into host immune responses and reactivation’s delicate balance, spanning innate and adaptive immunity. Viral factors’ disruption of this balance, as are interactions between viral antigens, immune cells, cytokine networks, and immune checkpoint pathways, are examined. Notably, the roles of T cells, natural killer cells, and antigen-presenting cells are discussed, highlighting their influence on disease progression. HBV reactivation’s impact on disease severity, hepatic flares, liver fibrosis progression, and hepatocellular carcinoma is detailed. Management strategies, including anti-viral and immunomodulatory approaches, are critically analyzed. The role of prophylactic anti-viral therapy during immunosuppressive treatments is explored alongside novel immunotherapeutic interventions to restore immune control and prevent reactivation. In conclusion, this comprehensive review furnishes a holistic view of the immunological mechanisms that propel HBV reactivation. With a dedicated focus on understanding its implications for disease progression and the prospects of efficient management strategies, this article contributes significantly to the knowledge base. The more profound insights into the intricate interactions between viral elements and the immune system will inform evidence-based approaches, ultimately enhancing disease management and elevating patient outcomes. The dynamic landscape of management strategies is critically scrutinized, spanning anti-viral and immunomodulatory approaches. The role of prophylactic anti-viral therapy in preventing reactivation during immunosuppressive treatments and the potential of innovative immunotherapeutic interventions to restore immune control and proactively deter reactivation.

show abstract